Vitiligo-like lesions in patients with melanoma treated with immunotherapy

European Journal of Dermatology

Volumn 7, Issue 7, 1997, Pages 522-524

  Buendia Eisman, Agustin ^a   Serrano Ortega, Salvio ^a   Del Olmo, Rosa Ortega ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Immunotherapy; Melanoma; Vitiligo like

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; RECOMBINANT ALPHA2 INTERFERON; THYMOSTIMULIN;

ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPIGMENTATION; IMMUNE RESPONSE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MELANOMA; PROGNOSIS; VITILIGO;

EID: 0030771102     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bystryn JC. The immunobiology of human malignant melanoma. Int J Dermatol 1980; 19: 375-8.
2. Sober AJ. Immunology and cutaneous malignant melanoma. Int J Dermatol 1976; 15: 1-19.
3. Delaunay MM. Melanome cutane et des muqueuses superficielles. Paris: Masson, 1992: 172.
4. Bystryn JC. Immune mechanisms in vitiligo. Immunol Ser 1989; 46: 447-73.
5. Naughton GK, Mahaffey M, Bystryn JC. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Med 1986; 181: 423-6.
6. Alabi GO, Falope ZF, Lekwauwa UG. Coexisting malignant melanoma and vitiligo in a Nigerian. West Afr J Med 1991; 10: 443-6.
7. Bystryn JC, Rigel D, Friedman RJ, et al. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 1053-5.
8. Lerner AB, Kirkwood JM. Vitiligo and melanoma: can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family ? J Am Acad Dermatol 1984; 11: 696-701.
9. Uda H, Takey M, Mishima Y. Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects.II.the IgG and C3 deposits in the skin. J Cutan Pathol 1984; 11: 114-24.
10. Takey M, Mishima Y, Uda H. Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects.I.Circulating antibodies for cultured melanoma cells. J Cutan Pathol 1984; 11: 107-13.
11. Bystryn JC. Immunology and immunotherapy of human malignant melanoma. Dermatol Clin 1985; 3: 327-34.
12. Koh HK, Sober AJ, Nakagawa H, et al. Malignant melanoma and vitiligo-like leucoderma: an electronic microscopic study. J Am Acad Dermatol 1983; 9: 696-708.
13. Barnes L, Nordlund JJ. Depigmentation: its significance in patients with melanoma. In: Mackie R, ed. Clinics in dermatology. Vol. 7, Pt 2. Philadelphia: JB Lippincott, 1989: 66-79.
14. Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M, Ferrone S, Fishman P. Melanoma-associated hypopigmentation: where are the antibodies? Am J Clin Oncol 1996; 19: 613-8.
15. Cavallari V, Cannavo S, Ussia A, Moretti G, Albanese A. Vitiligo associated with metastatic malignant melanoma. Int J Dermatol 1996; 35: 738-40.
16. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma a good prognostic sign. J Am Acad Dermatol 1983; 9: 689-96.
17. Summer WC, Foraker AG. Spontaneous regression of human melanoma. Cancer 1960; 16: 79.
18. Chosidow O, Guillaume JC. Traitement du mélanome métastasique par l'interleukine-2. Ann Dermatol Venereol 1992; 119: 65-73.
19. Wolkenstein P, Chosidow O, Guillaume JC, et al. Lésions vitiligoides au cours des mèlanomes métastases traités par interleukine-2: 4 observations. Ann Dermatol Venereol 1992; 119: 907-9.